Drug intelligence / Profile preview

N0651

Development stage: Preclinical
Lead developer: Naegis Pharmaceuticals
Modality: Small Molecules
Administration: Oral, Topical, Ophthalmic

Overview

N0651 is a preclinical-stage small molecule developed by Naegis Pharmaceuticals for the treatment of retinal and corneal diseases. It acts as a dual inhibitor of leukotriene production, effectively blocking the synthesis of both leukotriene B4 (LTB4) and cysteinyl leukotrienes (cysLTs). By targeting these inflammatory mediators, N0651 aims to protect ocular tissues from damage associated with chronic inflammation. The drug is being evaluated for administration via oral and topical ophthalmic routes.

Targets

CYSLTR2 (Cysteinyl leukotriene receptor 2)

Beyond the preview

Go deeper on N0651.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on N0651.

Explore the full profile